NCI awards $3.46 million grant to study resistance to acute myeloid leukemia treatment

Ann-Kathrin Eisfeld, MD, co-investigator, director of the Clara D. Bloomfield Center for Leukemia Outcomes Research and director for Precision Genomics Clinical Transformation, OSUCCC – JamesToday, we have limited ability to predict which patients will benefit from treatment and which patients are likely to relapse,. Our goal is to identify biological signals that can guide treatment decisions and ultimately help us develop better options for patients."

Eisfeld is leading the large-scale bulk sequencing efforts for the project. The Ohio State team is joined by principal investigator Catherine Choy Smith, MD, of UCSF, and additional co-investigator Linde Miles, PhD, of Cincinnati Children's Hospital Medical Center.

"Ultimately, we want to move closer to a future where treatment decisions are guided by the biology of each patient's leukemia," said Borate. "That could help more patients receive the therapies most likely to work for them while accelerating the development of new options for those with resistant disease."

Source:

Ohio State University Wexner Medical Center